Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
Identifieur interne : 003A67 ( Ncbi/Merge ); précédent : 003A66; suivant : 003A68Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
Auteurs : Jiayu Liao [États-Unis] ; George Way [États-Unis] ; Vipul Madahar [États-Unis]Source :
- Medicine in drug discovery [ 2590-0986 ] ; 2020.
Abstract
The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
DOI: 10.1016/j.medidd.2020.100037
PubMed: 32292909
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000124
- to stream PubMed, to step Curation: 000124
- to stream PubMed, to step Checkpoint: 000154
Links to Exploration step
pubmed:32292909Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.</title><author><name sortKey="Liao, Jiayu" sort="Liao, Jiayu" uniqKey="Liao J" first="Jiayu" last="Liao">Jiayu Liao</name><affiliation wicri:level="2"><nlm:affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside</wicri:cityArea></affiliation></author><author><name sortKey="Way, George" sort="Way, George" uniqKey="Way G" first="George" last="Way">George Way</name><affiliation wicri:level="2"><nlm:affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside</wicri:cityArea></affiliation></author><author><name sortKey="Madahar, Vipul" sort="Madahar, Vipul" uniqKey="Madahar V" first="Vipul" last="Madahar">Vipul Madahar</name><affiliation wicri:level="2"><nlm:affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32292909</idno><idno type="pmid">32292909</idno><idno type="doi">10.1016/j.medidd.2020.100037</idno><idno type="wicri:Area/PubMed/Corpus">000124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000124</idno><idno type="wicri:Area/PubMed/Curation">000124</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000124</idno><idno type="wicri:Area/PubMed/Checkpoint">000154</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000154</idno><idno type="wicri:Area/Ncbi/Merge">003A67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.</title><author><name sortKey="Liao, Jiayu" sort="Liao, Jiayu" uniqKey="Liao J" first="Jiayu" last="Liao">Jiayu Liao</name><affiliation wicri:level="2"><nlm:affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside</wicri:cityArea></affiliation></author><author><name sortKey="Way, George" sort="Way, George" uniqKey="Way G" first="George" last="Way">George Way</name><affiliation wicri:level="2"><nlm:affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside</wicri:cityArea></affiliation></author><author><name sortKey="Madahar, Vipul" sort="Madahar, Vipul" uniqKey="Madahar V" first="Vipul" last="Madahar">Vipul Madahar</name><affiliation wicri:level="2"><nlm:affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside</wicri:cityArea></affiliation></author></analytic><series><title level="j">Medicine in drug discovery</title><idno type="eISSN">2590-0986</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32292909</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2590-0986</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>13</Day></PubDate></JournalIssue><Title>Medicine in drug discovery</Title><ISOAbbreviation>Med Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.</ArticleTitle><Pagination><MedlinePgn>100037</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medidd.2020.100037</ELocationID><Abstract><AbstractText>The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.</AbstractText><CopyrightInformation>© 2020 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Jiayu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Way</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madahar</LastName><ForeName>Vipul</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Bourns College of Engineering, University of California at Riverside, 900 University Avenue, Riverside, California 92521.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Med Drug Discov</MedlineTA><NlmUniqueID>101765689</NlmUniqueID><ISSNLinking>2590-0986</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Host factor</Keyword><Keyword MajorTopicYN="N">Influenza virus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword><Keyword MajorTopicYN="N">drug discovery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32292909</ArticleId><ArticleId IdType="doi">10.1016/j.medidd.2020.100037</ArticleId><ArticleId IdType="pii">S2590-0986(20)30024-5</ArticleId><ArticleId IdType="pii">100037</ArticleId><ArticleId IdType="pmc">PMC7153514</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>J Virol. 2012 Jan;86(2):642-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22072786</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402</Citation><ArticleIdList><ArticleId IdType="pubmed">16801417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Pharmacol. 2016 Oct;30:106-115</Citation><ArticleIdList><ArticleId IdType="pubmed">27570127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>RNA Biol. 2011 Mar-Apr;8(2):270-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21593585</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Biosyst. 2012 Jun;8(6):1723-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22466055</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1997 Dec 5;278(5344):1803-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9388184</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18625765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Genet. 2008 Apr;9(4):267-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18319742</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2009 Mar 11;301(10):1034-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19255110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2010 Mar 05;7:53</Citation><ArticleIdList><ArticleId IdType="pubmed">20202225</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Microb Drug Resist. 2017 Mar;23(2):253-260</Citation><ArticleIdList><ArticleId IdType="pubmed">27203354</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2014 Aug;462-463:135-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24971706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Pharmacol. 2017 Aug 15;809:178-190</Citation><ArticleIdList><ArticleId IdType="pubmed">28533172</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2014 Oct;110:94-103</Citation><ArticleIdList><ArticleId IdType="pubmed">25108173</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1993 May 1;90(9):4171-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8387212</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Liao, Jiayu" sort="Liao, Jiayu" uniqKey="Liao J" first="Jiayu" last="Liao">Jiayu Liao</name></region><name sortKey="Madahar, Vipul" sort="Madahar, Vipul" uniqKey="Madahar V" first="Vipul" last="Madahar">Vipul Madahar</name><name sortKey="Way, George" sort="Way, George" uniqKey="Way G" first="George" last="Way">George Way</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003A67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:32292909
|texte= Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32292909" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |